JP2006503031A - 拒食症（ａｎ）及び過食症を治療するためのエイコサペンタエン酸（ｅｐａ） - Google Patents
拒食症（ａｎ）及び過食症を治療するためのエイコサペンタエン酸（ｅｐａ） Download PDFInfo
- Publication number
- JP2006503031A JP2006503031A JP2004535695A JP2004535695A JP2006503031A JP 2006503031 A JP2006503031 A JP 2006503031A JP 2004535695 A JP2004535695 A JP 2004535695A JP 2004535695 A JP2004535695 A JP 2004535695A JP 2006503031 A JP2006503031 A JP 2006503031A
- Authority
- JP
- Japan
- Prior art keywords
- epa
- patient
- use according
- treatment
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 title claims abstract description 57
- 229960005135 eicosapentaenoic acid Drugs 0.000 title claims abstract description 57
- 235000020673 eicosapentaenoic acid Nutrition 0.000 title claims abstract description 57
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 title claims abstract description 57
- 208000000103 Anorexia Nervosa Diseases 0.000 title claims abstract description 41
- 208000032841 Bulimia Diseases 0.000 title claims abstract description 14
- 206010006550 Bulimia nervosa Diseases 0.000 title claims abstract description 13
- 238000011282 treatment Methods 0.000 title claims description 51
- 238000000034 method Methods 0.000 claims abstract description 18
- 208000035850 clinical syndrome Diseases 0.000 claims abstract description 7
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 16
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 12
- 239000002552 dosage form Substances 0.000 claims description 12
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 235000020778 linoleic acid Nutrition 0.000 claims description 9
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 9
- 235000021342 arachidonic acid Nutrition 0.000 claims description 8
- 229940114079 arachidonic acid Drugs 0.000 claims description 8
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 7
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 6
- 125000004494 ethyl ester group Chemical class 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 229960004232 linoleic acid Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 235000015872 dietary supplement Nutrition 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000013589 supplement Substances 0.000 claims description 3
- 150000003626 triacylglycerols Chemical class 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 description 30
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 description 30
- 229960002600 icosapent ethyl Drugs 0.000 description 26
- 208000024891 symptom Diseases 0.000 description 11
- 235000013305 food Nutrition 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 230000006872 improvement Effects 0.000 description 9
- 230000003340 mental effect Effects 0.000 description 8
- 208000030814 Eating disease Diseases 0.000 description 7
- 208000019454 Feeding and Eating disease Diseases 0.000 description 7
- 235000020805 dietary restrictions Nutrition 0.000 description 7
- 235000014632 disordered eating Nutrition 0.000 description 7
- 201000000736 Amenorrhea Diseases 0.000 description 6
- 206010001928 Amenorrhoea Diseases 0.000 description 6
- 231100000540 amenorrhea Toxicity 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 238000009231 family therapy Methods 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 230000004630 mental health Effects 0.000 description 6
- 230000006996 mental state Effects 0.000 description 6
- 208000019901 Anxiety disease Diseases 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 208000022531 anorexia Diseases 0.000 description 4
- 206010061428 decreased appetite Diseases 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000001671 psychotherapy Methods 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000005686 eating Nutrition 0.000 description 3
- 230000002996 emotional effect Effects 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 230000005906 menstruation Effects 0.000 description 3
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 3
- 238000002369 psychoeducation Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 206010053759 Growth retardation Diseases 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 206010036155 Poor peripheral circulation Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 230000036471 bradycardia Effects 0.000 description 2
- 208000006218 bradycardia Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000009223 counseling Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 231100000001 growth retardation Toxicity 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 239000008141 laxative Substances 0.000 description 2
- 238000007449 liver function test Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000020802 micronutrient deficiency Nutrition 0.000 description 2
- 230000002969 morbid Effects 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000002294 pubertal effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000036301 sexual development Effects 0.000 description 2
- 235000021055 solid food Nutrition 0.000 description 2
- 238000011272 standard treatment Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical group CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000035943 Aphagia Diseases 0.000 description 1
- 206010004716 Binge eating Diseases 0.000 description 1
- 101150031621 CGAS gene Proteins 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 102100031256 Cyclic GMP-AMP synthase Human genes 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010061832 Eating disorder symptom Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010016280 Fear of weight gain Diseases 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 208000012766 Growth delay Diseases 0.000 description 1
- 206010056438 Growth hormone deficiency Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010024870 Loss of libido Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010029897 Obsessive thoughts Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000037063 Thinness Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- -1 amides Esters Chemical class 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000014679 binge eating disease Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 231100000867 compulsive behavior Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- 230000004970 emotional disturbance Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000008571 general function Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000005032 impulse control Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 206010048828 underweight Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 229940091251 zinc supplement Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0221480.7A GB0221480D0 (en) | 2002-09-16 | 2002-09-16 | Treatment of anorexia nervosa (AN) and bulimia |
| PCT/GB2003/003985 WO2004024136A1 (en) | 2002-09-16 | 2003-09-16 | Eicosapentaenoic acid (epa) for treating anorexia nervosa (an) and bulimia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006503031A true JP2006503031A (ja) | 2006-01-26 |
| JP2006503031A5 JP2006503031A5 (https=) | 2006-11-02 |
Family
ID=9944164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004535695A Pending JP2006503031A (ja) | 2002-09-16 | 2003-09-16 | 拒食症（ａｎ）及び過食症を治療するためのエイコサペンタエン酸（ｅｐａ） |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20060135608A1 (https=) |
| EP (1) | EP1556028A1 (https=) |
| JP (1) | JP2006503031A (https=) |
| KR (1) | KR20050042823A (https=) |
| CN (1) | CN1694694A (https=) |
| AU (1) | AU2003269138A1 (https=) |
| BR (1) | BR0317857A (https=) |
| CA (1) | CA2499142A1 (https=) |
| GB (1) | GB0221480D0 (https=) |
| HR (1) | HRP20050245A2 (https=) |
| IS (1) | IS7744A (https=) |
| MX (1) | MXPA05002943A (https=) |
| NO (1) | NO20051847L (https=) |
| NZ (1) | NZ538793A (https=) |
| PL (1) | PL375726A1 (https=) |
| RS (1) | RS20050226A (https=) |
| RU (1) | RU2330653C2 (https=) |
| TW (1) | TW200410682A (https=) |
| WO (1) | WO2004024136A1 (https=) |
| ZA (1) | ZA200502161B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003048831A (ja) | 2001-08-02 | 2003-02-21 | Suntory Ltd | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
| WO2005046668A1 (ja) * | 2003-11-14 | 2005-05-26 | Mochida Pharmaceutical Co., Ltd. | 言語障害予防・治療剤 |
| JP4993852B2 (ja) | 2004-09-17 | 2012-08-08 | サントリーホールディングス株式会社 | ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物 |
| JP5967855B2 (ja) | 2005-06-30 | 2016-08-10 | サントリーホールディングス株式会社 | 日中活動量の低下および／又はうつ症状の改善作用を有する組成物 |
| EP2098229A4 (en) | 2006-12-28 | 2010-03-10 | Suntory Holdings Ltd | NERVE REGENERATION MEDIUM |
| DK2121576T3 (en) | 2007-02-15 | 2016-02-15 | Ct De Rech Sur Les Biotechnologies Marine | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
| US8816110B2 (en) | 2007-02-15 | 2014-08-26 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
| CA2677670C (en) | 2007-03-20 | 2010-08-03 | Centre De Recherche Sur Les Biotechnologies Marines | Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof |
| US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
| EP3318255B1 (en) * | 2009-06-15 | 2021-03-10 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating stroke in a subject on concomitant statin therapy |
| EP2673371A1 (en) * | 2011-02-11 | 2013-12-18 | E.I. Du Pont De Nemours And Company | An eicosapentaenoic acid concentrate |
| US9447020B2 (en) | 2013-10-31 | 2016-09-20 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
| RU2545988C1 (ru) * | 2013-11-12 | 2015-04-10 | Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр Департамента здравоохранения города Москвы | Способ лечения хронического запора и функциональной анорексии |
| WO2019153073A1 (en) | 2018-02-07 | 2019-08-15 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof |
| WO2019204218A1 (en) * | 2018-04-16 | 2019-10-24 | Quadrant Biosciences Inc. | Salivary microrna levels in anorexia nervosa provide a liquid biopsy of metabolic and neuropsychiatric status |
| EP3787614B1 (en) | 2018-05-03 | 2024-07-31 | SCF Pharma Inc. | Polyunsaturated fatty acid monoglycerides, compositions and use thereof for modulating a microbiota composition of a subject |
| CN109276262B (zh) * | 2018-07-30 | 2021-01-26 | 中国科学院心理研究所 | 一种用于筛选高危进食障碍的检测系统 |
| US12226390B2 (en) | 2019-07-21 | 2025-02-18 | Scf Pharma Inc. | Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof |
| US12144786B2 (en) | 2020-03-27 | 2024-11-19 | Homeostasis Therapeutics LLC | Methods of treatment for anorexia nervosa, bulimia and related clinical syndromes |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11508282A (ja) * | 1996-04-25 | 1999-07-21 | アボツト・ラボラトリーズ | 悪液質および食欲不振の予防および治療方法 |
| WO2000044361A2 (en) * | 1999-01-27 | 2000-08-03 | Laxdale Limited | Highly purified ethyl epa and other epa derivatives for psychiatric and neurological disorders |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9224809D0 (en) * | 1992-11-26 | 1993-01-13 | Scotia Holdings Plc | Schizophrenia |
-
2002
- 2002-09-16 GB GBGB0221480.7A patent/GB0221480D0/en not_active Ceased
-
2003
- 2003-09-16 AU AU2003269138A patent/AU2003269138A1/en not_active Abandoned
- 2003-09-16 HR HR20050245A patent/HRP20050245A2/hr not_active Application Discontinuation
- 2003-09-16 BR BR0317857-9A patent/BR0317857A/pt not_active IP Right Cessation
- 2003-09-16 NZ NZ538793A patent/NZ538793A/en unknown
- 2003-09-16 PL PL03375726A patent/PL375726A1/xx not_active Application Discontinuation
- 2003-09-16 JP JP2004535695A patent/JP2006503031A/ja active Pending
- 2003-09-16 RU RU2005107416/14A patent/RU2330653C2/ru not_active IP Right Cessation
- 2003-09-16 RS YUP-2005/0226A patent/RS20050226A/sr unknown
- 2003-09-16 CA CA002499142A patent/CA2499142A1/en not_active Abandoned
- 2003-09-16 WO PCT/GB2003/003985 patent/WO2004024136A1/en not_active Ceased
- 2003-09-16 KR KR1020057004483A patent/KR20050042823A/ko not_active Withdrawn
- 2003-09-16 MX MXPA05002943A patent/MXPA05002943A/es not_active Application Discontinuation
- 2003-09-16 CN CNA038251698A patent/CN1694694A/zh active Pending
- 2003-09-16 EP EP03750919A patent/EP1556028A1/en not_active Ceased
- 2003-09-16 TW TW092125483A patent/TW200410682A/zh unknown
- 2003-09-16 US US10/528,114 patent/US20060135608A1/en not_active Abandoned
-
2005
- 2005-03-15 ZA ZA200502161A patent/ZA200502161B/en unknown
- 2005-03-15 IS IS7744A patent/IS7744A/is unknown
- 2005-04-15 NO NO20051847A patent/NO20051847L/no not_active Application Discontinuation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11508282A (ja) * | 1996-04-25 | 1999-07-21 | アボツト・ラボラトリーズ | 悪液質および食欲不振の予防および治療方法 |
| WO2000044361A2 (en) * | 1999-01-27 | 2000-08-03 | Laxdale Limited | Highly purified ethyl epa and other epa derivatives for psychiatric and neurological disorders |
Non-Patent Citations (6)
| Title |
|---|
| JPN6010004980, Ｋａｔｅ Ｌｏｖｅｔｔ, Ｂｕｌｉｍｉａ ａｎｄ Ｄｅｐｒｅｓｓｉｏｎ, 19870427, ｈｔｔｐ：／／ｗｗｗ．ｖａｎｄｅｒｂｉｌｔ．ｅｄｕ／ＡｎＳ／ｐｓｙｃｈｏｌｏｇｙ * |
| JPN6010004982, Ｊａｍｅｓ Ｃａｌｄｗｅｌｌ, Ｅａｔｉｎｇ Ｄｉｓｏｒｄｅｒｓ ａｎｄ Ｐｅｒｓｏｎａｌｉｔｙ Ｄｉｓｏｒｄｅｒｓ， Ａ Ｓｔｕｄｙ Ｉｎ Ｃｏｍｏｒｂｉｄｉｔｙ, 19970430, ｈｔｔｐ：／／ｗｗｗ．ｖａｎｄｅｒｂｉｌｔ．ｅｄｕ／ＡｎＳ／ｐｓｙｃｈｏｌｏｇｙ * |
| JPN6010004984, Ｋｉｍｂｅｒｌｙ Ｐｕｌｓｅ, Ｔｈｅ Ｃｏｍｏｒｂｉｄｉｔｙ ｏｆ Ａｎｘｉｅｔｙ Ｄｉｓｏｒｄｅｒｓ ａｎｄ Ｅａｔｉｎｇ Ｄｉｓｏｒｄｅｒｓ, 19990404, ｈｔｔｐ：／／ｗｗｗ．ｖａｎｄｅｒｂｉｌｔ．ｅｄｕ／ＡｎＳ／ｐｓｙｃｈｏｌｏｇｙ * |
| JPN6010004988, Ａｌｉｋａ Ｍｏｉｔｒａ, Ｄｅｐｒｅｓｓｉｏｎ ａｎｄ Ｂｏｄｙ Ｉｍａｇｅ, 19990404, ｈｔｔｐ：／／ｗｗｗ．ｖａｎｄｅｒｂｉｌｔ．ｅｄｕ／ＡｎＳ／ｐｓｙｃｈｏｌｏｇｙ * |
| JPN6010004989, 日本臨床, 200103, ５９（３）, ５４０−５４３ * |
| JPN6010004993, 医薬ジャーナル, 1994, ３０（８）, ２０６３−２０６８ * |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200502161B (en) | 2005-09-15 |
| RS20050226A (sr) | 2007-09-21 |
| NO20051847L (no) | 2005-04-15 |
| PL375726A1 (en) | 2005-12-12 |
| EP1556028A1 (en) | 2005-07-27 |
| CA2499142A1 (en) | 2004-03-25 |
| HRP20050245A2 (en) | 2005-10-31 |
| CN1694694A (zh) | 2005-11-09 |
| BR0317857A (pt) | 2005-12-06 |
| GB0221480D0 (en) | 2002-10-23 |
| AU2003269138A1 (en) | 2004-04-30 |
| RU2330653C2 (ru) | 2008-08-10 |
| US20060135608A1 (en) | 2006-06-22 |
| WO2004024136A1 (en) | 2004-03-25 |
| TW200410682A (en) | 2004-07-01 |
| MXPA05002943A (es) | 2005-06-03 |
| IS7744A (is) | 2005-03-15 |
| KR20050042823A (ko) | 2005-05-10 |
| NZ538793A (en) | 2007-05-31 |
| RU2005107416A (ru) | 2006-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006503031A (ja) | 拒食症（ａｎ）及び過食症を治療するためのエイコサペンタエン酸（ｅｐａ） | |
| CN100423718C (zh) | 治疗精神性和神经性疾病的高纯乙基epa及其他epa衍生物 | |
| CN103298462A (zh) | 降低暴食或强迫进食的方法 | |
| Sehgal et al. | The imperatives of leprosy treatment in the pre‐and post‐global leprosy elimination era: appraisal of changing the scenario to current status | |
| US20260053764A1 (en) | Composition for preventing deterioration in cognitive function and/or improving cognitive function | |
| CN114452305A (zh) | 单形拟杆菌用于制造预防与治疗焦虑抑郁症药物中的应用 | |
| Dighikar et al. | A Rare Case of Wilson’s Disease in a 17 Years Old Girl | |
| Shankar et al. | Ayurvedic management of neurological deficits post COVID-19 vaccination-A report of two cases | |
| Yavuz et al. | Efficacy, safety, and growth outcomes of ketogenic diet therapy in children under two years of age | |
| Lean | Management of obesity and overweight | |
| Cicero et al. | Complementary and Alternative Medicine for Hypertension: What Evidence is There for Herbalist Suggestions? | |
| JP6143215B2 (ja) | 高脂肪食への嗜好性を軽減させるための医薬組成物、飲食品組成物または飲食品添加剤 | |
| JP6281919B2 (ja) | 高脂肪食への嗜好性を軽減させるための医薬組成物、飲食品組成物または飲食品添加剤 | |
| Mathur | Diabetes mellitus | |
| Pira et al. | Use Of Teduglutide In The Treatment Of Chronic Intestinal Failure Associated With Short Bowel Syndrome In Adults: Real-Life Experience Of The Iicb Reference Centre Of The AOU CittÀ Della Salute E Della Scienza Of Turin | |
| LIST | Standard Treatment guidelines | |
| Chongchareon et al. | A self-care promotion model for controlling blood sugar in type 2 diabetes | |
| Yacoub et al. | Case Report Cannabinoid Hyperemesis Syndrome: A Case Study in a Tunisian Young Man | |
| Walshe et al. | Dysphagia in an individual with Alzheimer’s disease | |
| Saibil | Crohn's Disease and Ulcerative Colitis: Everything You Need To Know-The Complete Practical Guide | |
| Baron | Crohn Disease in Children: This chronic illness can be painful and isolating, but new treatments may help. | |
| Escott-Stump | Theme Three Homeostasis and Regulation | |
| Ubogu | Neurology Oral Boards Review: A Concise and Systematic Approach to Clinical Practice | |
| Antonelli et al. | One Year Monitoring of a Lipase Rich Pancreatic Enzyme Preparation (Enzipan®) in the Treatment of Severe Lipid Maldigestion of Cystic Fibrosis | |
| Kinkel | How To Find Solutions And Even A Cure? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060915 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060915 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100205 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100720 |